Business Context and Reporting Period
This Form 8-K filing by Trisalus Life Sciences, Inc. (TLSI) reports a leadership transition and a new executive compensation program. The report date is January 4, 2025, with the leadership changes effective January 6, 2025.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and executive compensation arrangements.
Material Changes
- Leadership Transition: James Young was promoted to Chief Financial Officer, Secretary, Treasurer, and principal financial and accounting officer. Sean Murphy was appointed Chief Manufacturing, Strategy and Business Development Officer.
- Role Reassignment: Mr. Murphy previously served as CFO and will continue as a Board member. Mr. Young previously served as Senior Vice President of Investor Relations and Treasurer.
- Compensation Adjustments:
- Mr. Young's annual base salary is set at $420,000 with a target performance bonus of up to 50% of base salary.
- Mr. Murphy's annual base salary was adjusted to $450,000.
- Mr. Murphy's severance pay for "Discharge Without Cause" or "Resignation for Good Reason" was reduced to six months of salary.
- Salary Investment Program: A program was approved allowing executives to reduce 2025 base salary in exchange for Restricted Stock Units (RSUs). As of December 31, 2024, executives elected to invest an aggregate of $515,052.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or general risk factors. Specific contingencies related to executive employment include:
- Severance for Mr. Young: Entitled to six months of base salary upon termination without cause or for good reason. In the event of a Change of Control within one year, severance increases to 12 months of base salary, full target bonus, one year of benefits, and full vesting of equity.
- Severance for Mr. Murphy: Entitled to six months of base salary upon termination without cause or for good reason.
Key Facts for Investor Verification
- Verify the impact of the CFO transition on the company's financial reporting and investor relations strategy.
- Confirm the total equity grant value associated with the $515,052 Salary Investment Program once RSUs are granted (expected around February 18, 2025).
- Review the full text of the Executive Employment Agreements (Exhibits 10.1 and 10.2) for detailed definitions of "Discharge Without Cause," "Resignation for Good Reason," and "Change of Control."
- Monitor future filings for the actual issuance of RSUs under the Salary Investment Program.